Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica Picks up ADME-related IP, Lab Space, Research Staff from ArQule

NEW YORK, June 23 - Inpharmatica said today that it plans to acquire certain assets relating to ADME (absorption, distribution, metabolism, and excretion) research from ArQule.


Specifically, Inpharmatica will take over ArQule's 10,000-square-foot Cambridge, UK, laboratories and will license some of the company's intellectual property. Fifteen of ArQule's Cambridge-based research staff will join Inpharmatica following the deal, which is subject to certain third party consents and agreements.


Financial terms of the acquisition were not disclosed.


Inpharmatica said it plans to use the newly acquired technology to enhance its PharmaCarta chemogenomics technology platform and to advance its internal discovery programs to the pre-clinical phase.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.